| Safety, pharmacokinetics, and antiviral activity of AT-527, a novel purine nucleotide prodrug, in hepatitis C virus-infected subjects with or without cirrhosis E Berliba, M Bogus, F Vanhoutte, PJ Berghmans, SS Good, A Moussa, ... Antimicrobial agents and chemotherapy 63 (12), 10.1128/aac. 01201-19, 2019 | 39 | 2019 |
| A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19 D Singh, M Bogus, V Moskalenko, R Lord, EJ Moran, GD Crater, ... European Respiratory Journal 58 (4), 2021 | 38 | 2021 |
| AT-527, a pan-genotypic purine nucleotide prodrug, exhibits potent antiviral activity in subjects with chronic hepatitis C X Zhou, E Berliba, F Vanhoutte, M Bogus, PJ Berghmans, K Pietropaolo, ... International Liver Congress, 2018 | 12 | 2018 |
| A phase 1a study of AT-527, a novel pan-genotypic purine nucleotide prodrug inhibitor of hepatitis C virus (HCV) XJ Zhou, F Vanhoutte, E Berliba, PJ Berghmans, M Bogus, SS Good, ... Headache 2 (2), 3, 2017 | 11 | 2017 |
| Aspecte clinico-imunologice a pacienţilor cu nefrolitiază E Ceban, N Isac, A Galescu, P Banov, M Boguş, V Botnari, A Tănase Analele Ştiinţifice ale USMF „N. Testemiţanu” 11 (4), 118-122, 2010 | 4 | 2010 |
| Necesitatea aplicării stentului ureteral după ureteroscopii cu litotriţie şi litextracţie in litiaza ureterală V Ghicavîi, A Galescu, E Ceban, C Lupaşco, A Bradu, M Boguş, ... Arta Medica 45 (2S), 94-96, 2011 | 3 | 2011 |
| Metodologia aplicării nefrolitotomiei percutane în chirurgia rinichiului litiazic V Botnari, E Ceban, A Galescu, A Tănase, P Banov, A Bradu, M Boguş Analele Ştiinţifice ale USMF „N. Testemiţanu” 11 (4), 128-133, 2010 | 2 | 2010 |
| Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial J Belperio, T Nguyen, DA Lombardi, M Bogus, V Moskalenko, D Singh, ... BMJ Open Respiratory Research 10 (1), e001627, 2023 | 1 | 2023 |
| A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1 D Singh, M Bogus, V Moskalenko, R Lord, EJ Moran, GD Crater, ... medRxiv, 2021.03. 09.21252944, 2021 | 1 | 2021 |
| HCV viral kinetic analysis predicts shorter treatment duration with AT-527, a purine nucleotide prodrug with potent pan-genotypic antiviral activity in HCV-infected subjects … XJ Zhou, E Berliba, A Jucov, M BOGUS, SS GOOD, A MOUSSA, ... HEPATOLOGY 70, 986A-987A, 2019 | 1 | 2019 |
| AT-527, a purine nucleotide prodrug, exhibits potent pan-genotypic antiviral activity in HCV-infected subjects with cirrhosis XJ Zhou, E Berliba, M Bogus, F Vanhoutte, PJ Berghmans, S Good, ... HEPATOLOGY 68, 585A-585A, 2018 | 1 | 2018 |
| Pielonefrita acută: etiologie, corelaţii clinico-evolutive, tratament V Platon, C Lupaşcu, M Boguş, I Milici, P Banov Arta Medica 45 (2S), 120-122, 2011 | | 2011 |
| A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part D Singh, M Bogus, V Moskalenko, R Lord, EJ Moran, GD Crater, ... | | |
